8-K: Acadia Q2 2025 Revenue Up 9%, Raises NUPLAZID Outlook

Acadia Pharmaceuticals reported strong second-quarter 2025 financial results with total revenues up 9% year-over-year, driven by growth in NUPLAZID and DAYBUE sales, and raised its NUPLAZID sales guidance.

Summary

• Total revenues for the second quarter of 2025 were $264.6 million, an increase of 9% compared to $241.963 million in Q2 2024.
• NUPLAZID net product sales reached $168.5 million in Q2 2025, up 7% year-over-year from $157.4 million in Q2 2024, including 5% volume growth.
• DAYBUE net product sales were $96.1 million for Q2 2025, an increase of 14% compared to $84.6 million in Q2 2024, driven by growth in unit sales and reaching a record high of 987 unique patients receiving shipments.
• Net income for Q2 2025 was $26.7 million, or $0.16 per common share, down from $33.4 million, or $0.20 per common share, in Q2 2024, primarily due to a higher effective tax rate.
• Cash, cash equivalents, and investment securities totaled $762.0 million as of June 30, 2025, an increase from $756.0 million at December 31, 2024.
• Full-year 2025 guidance for NUPLAZID net product sales was raised to a range of $665 million to $690 million (from $650 million to $690 million), leading to an updated total revenue guidance of $1.045 billion to $1.095 billion (from $1.030 billion to $1.095 billion). All other prior 2025 guidance was reiterated.
• Completed enrollment in the COMPASS PWS Phase 3 study of ACP-101 in Prader-Willi Syndrome, with top-line results expected in early Q4 2025.
• Achieved two significant patent litigation wins for NUPLAZID, securing market exclusivity until 2030 for the composition-of-matter patent and 2038 for the formulation patent.
• Hosted an inaugural R&D Day in June, highlighting nine disclosed programs, with seven Phase 2 or Phase 3 studies expected to initiate during 2025-2026 and five readouts anticipated through 2027.
• Commenced named patient supply of trofinetide (DAYBUE) in Europe, Israel, and select rest of the world countries.

Sentiment

Score: 7

Explanation: The company reported strong revenue growth for both key products and raised its full-year guidance for NUPLAZID sales, indicating positive commercial momentum. Significant patent wins for NUPLAZID also de-risk future revenue streams. However, the decline in net income due to a higher effective tax rate and increased SG&A expenses temper the overall positive sentiment, suggesting some profitability pressures despite top-line growth.

Positives

• Total revenues increased by 9% year-over-year to $264.6 million.
• NUPLAZID net product sales grew 7% year-over-year to $168.5 million, driven by strong commercial execution and increased direct-to-consumer engagement, with 5% volume growth.
• DAYBUE net product sales increased 14% year-over-year to $96.1 million, reaching a record high of 987 unique patients receiving shipments in Q2 2025.
• Raised the low end of full-year 2025 NUPLAZID net product sales guidance to $665-$690 million, indicating increased confidence in product performance.
• Achieved two significant patent litigation wins for NUPLAZID, securing market exclusivity until 2030 (composition-of-matter) and 2038 (formulation).
• Completed enrollment in the COMPASS PWS Phase 3 study of ACP-101, with top-line results expected early Q4 2025.
• Hosted inaugural R&D Day, showcasing a deep pipeline with seven Phase 2 or Phase 3 studies expected to initiate during 2025-2026 and five readouts anticipated through 2027.
• Cash, cash equivalents, and investment securities increased to $762.0 million as of June 30, 2025, from $756.0 million at December 31, 2024.
• Commenced named patient supply of trofinetide for eligible patients based upon healthcare professional requests in Europe, Israel, and select rest of the world countries.

Negatives

• Net income decreased to $26.7 million ($0.16 per share) in Q2 2025 from $33.4 million ($0.20 per share) in Q2 2024.
• The decline in net income was primarily due to a higher effective tax rate, driven by reduced utilization of tax credits and net operating loss carryforwards under U.S. GAAP.
• Selling, general and administrative expenses increased to $133.5 million in Q2 2025 from $117.1 million in Q2 2024, primarily due to increased expenditures for DAYBUE and NUPLAZID in the U.S., including the planned expansion of the DAYBUE commercial team.

Risks

• Dependency on the continued successful commercialization of products and ability to maintain or increase sales.
• Plans to commercialize DAYBUE globally and trofinetide in the EU.
• Costs of commercialization plans and development programs, and the financial impact or revenues from any commercialization undertaken.
• Ability to obtain necessary regulatory approvals for product candidates and, if and when approved, market acceptance of products.
• Risks associated with clinical trials and their outcomes, including risks of unsuccessful enrollment and negative or inconsistent results.
• Dependence on third-party collaborators, clinical research organizations, manufacturers, suppliers, and distributors.
• Impact of competitive products and therapies.
• Ability to generate or obtain the necessary capital to fund operations.
• Ability to grow, equip, and train specialized sales forces.
• Ability to manage the growth and complexity of the organization.
• Ability to maintain, protect, and enhance intellectual property.
• Ability to continue to stay in compliance with applicable laws and regulations.

Future Outlook

Acadia Pharmaceuticals is raising the low end of its full-year 2025 NUPLAZID net product sales guidance to $665-$690 million, resulting in an updated total revenue guidance of $1.045-$1.095 billion. All other prior 2025 guidance, including DAYBUE sales, R&D, and SG&A expenses, is reiterated. Top-line results for the COMPASS PWS Phase 3 study of ACP-101 in Prader-Willi Syndrome are expected in early Q4 2025. The company plans to initiate seven Phase 2 or Phase 3 studies during 2025-2026 and anticipates five readouts through 2027, reinforcing its R&D strategy and pipeline depth.

Management Comments

• "Acadia continued to build momentum in the second quarter, resulting in total revenue of $264.6 million."
• "NUPLAZID delivered a very strong quarter, particularly in terms of referrals and new patient starts, driven by strong commercial execution and increased engagement from our direct-to-consumer campaigns."
• "DAYBUE grew 14% year-over-year and reached its highest paid patient count to date, reflecting disciplined execution of our plan to accelerate growth."
• "In addition, we recently hosted our inaugural R&D Day showcasing the depth of our pipeline and its potential to drive our long-term value."

Industry Context

The pharmaceutical industry, particularly in neurological and rare diseases, is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Acadia's focus on these areas, with two FDA-approved products (NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome) and a robust pipeline, positions it within a specialized and high-value segment. The company's patent wins for NUPLAZID are crucial for maintaining market exclusivity against generic competition, a common challenge in the industry. The expansion of its commercial team and global supply initiatives for DAYBUE reflect efforts to maximize market penetration and address unmet medical needs in these niche therapeutic areas.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks.

Management Changes

Legal Proceedings

• Achieved two significant patent litigation wins securing market exclusivity for NUPLAZID.
• Affirmed the validity of the composition-of-matter patent for pimavanserin, with an expiry date in 2030.
• Upheld the formulation patent covering the marketed 34 mg capsule, with an expiry date in 2038.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, increased guidance for a key product, and patent wins securing long-term revenue streams. Net income decline and increased expenses could be a concern.
• Patients: Continued access to NUPLAZID and DAYBUE, with DAYBUE reaching more unique patients and commencing supply in new regions (Europe, Israel, etc.). Potential for new treatments from the pipeline (e.g., ACP-101 for Prader-Willi Syndrome).
• Employees: Expansion of the DAYBUE commercial team and new executive appointments indicate growth and potential for new roles.
• Customers (Healthcare Professionals): Increased engagement and support for NUPLAZID and DAYBUE.

Next Steps

• Top-line results expected for COMPASS PWS Phase 3 study of ACP-101 in early Q4 2025.
• Seven Phase 2 or Phase 3 studies expected to initiate during 2025-2026.
• Five readouts anticipated through 2027.
• Continued disciplined execution of the plan to accelerate DAYBUE growth.
• Further expansion of the DAYBUE commercial team.
• Ongoing efforts to drive innovation and decision-making across the organization through enterprise-wide data, IT, cybersecurity, and analytics.
• Continued commercialization of DAYBUE globally and trofinetide in the EU.

Key Dates

Recommendation

While Acadia Pharmaceuticals demonstrated strong revenue growth for its key products and raised its NUPLAZID sales guidance, indicating positive commercial momentum and market confidence, the decline in net income due to a higher effective tax rate and increased operating expenses warrants caution. The patent wins are significant positives, securing long-term exclusivity. However, the stock has likely already priced in some of these positives. Given the mixed financial performance (strong top-line, weaker bottom-line due to tax/expenses) and the inherent risks associated with a biotech pipeline (clinical trial outcomes, regulatory approvals), a "hold" recommendation is appropriate. Investors should monitor future profitability trends and pipeline advancements, particularly the ACP-101 Phase 3 results, before making further investment decisions.

Keywords

Acadia Pharmaceuticals, ACAD, NUPLAZID, pimavanserin, DAYBUE, trofinetide, Parkinson's disease psychosis, Rett syndrome, Prader-Willi syndrome, Alzheimer's disease psychosis, neurological diseases, rare diseases, biotech, pharmaceuticals, Q2 2025 earnings, financial results, clinical trials, patent litigation